What Syntometrine Treats: Main Uses and Benefits

Syntometrine is commonly used to help prevent postpartum hemorrhage (PPH), a condition marked by conditions associated with acute or disruptive episodes of excessive blood loss immediately following childbirth. It is relevant in clinical settings that involve acute or unstable symptom patterns, and may assist in minimizing the potential for significant blood loss.

The primary use classifications are the prevention of PPH, the supportive management of the third stage of labor, and addressing uterine atony (muscle weakness). It is applied to address symptom clusters that may become intense or disruptive, specifically the failure of the uterus to contract after delivery. By promoting uterine contraction, it helps manage symptoms related to organ-specific functional stress, thereby contributing to easing the overall symptom load associated with acute bleeding.

“The medication is applied in clinical settings that involve acute symptom patterns, supporting the patient during episodes of heightened discomfort.”

The medication is commonly used when supportive symptom management is appropriate as a necessary component of the active management of the third stage of labor protocol. This application is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

---

Quick Fact: Relief for Symptoms of Systemic Imbalance

---

Regulatory References

1. Health Products Regulatory Authority (HPRA) product information

Who can and cannot use Syntometrine?

The official eligibility profile for Syntometrine is highly specific and strictly defined by regulatory authorities to limit its use to a narrow physiological context.

---

Populations for Whom Use is Allowed

Syntometrine is approved for use exclusively in adult women for the active management of the third stage of labour. Its administration is restricted to the period immediately following delivery of the anterior shoulder or the last child.

---

Absolute Contraindications (Must Not Use)

The medicine is contraindicated in several patient groups. These absolute prohibitions apply to patients with known hypersensitivity to oxytocin or ergometrine, and those with pre-existing severe systemic conditions like severe hypertension, pre-eclampsia, eclampsia, severe cardiac disorders, occlusive vascular disease, or sepsis. Use is prohibited throughout pregnancy and for the induction of labour or before the last delivery. Patients with severe hepatic or severe renal impairment must also not use this medicine.

---

Restricted and Age-Related Eligibility

Use requires caution in patients with mild or moderate hypertension, non-severe cardiac disorders, or coronary artery disease. The drug is not indicated for use in children. While breastfeeding, repeated use should be avoided as the ergometrine component may suppress lactation.

Interactions with other medicines and products

Syntometrine's official interaction profile is defined by two primary pharmacological mechanisms involving its Ergometrine maleate and Oxytocin components. All interaction statements are derived strictly from government regulatory documentation.

---

Pharmacokinetic Interactions (CYP3A4 Pathway)

The Ergometrine maleate component is metabolized via the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors is officially advised to be avoided. This pharmacokinetic interaction reduces the drug's clearance, which results in an increase in the plasma concentration and exposure of Ergometrine. This class includes specific macrolide antibiotics (such as erythromycin) and azole antifungals (such as ketoconazole). Conversely, CYP3A4 inducers, such as rifampicin, are documented to potentially decrease the drug's clinical effect. Consumption of Grapefruit Juice is not recommended, as it is noted as a weak CYP3A4 inhibitor.

---

Pharmacodynamic Interactions

The product's powerful effects on uterine muscle tone and blood vessels lead to multiple pharmacodynamic interactions. Co-administration with other Vasoconstrictors or Sympathomimetics may enhance the blood pressure-raising (pressor) effect, posing a risk for severe postpartum hypertension, particularly when administered during certain types of anesthesia. Additive vasoconstriction is also documented with other ergot alkaloids and anti-migraine Triptan medicines. Separately, the product can potentiate the uterine action of co-administered Prostaglandins and their analogues, while some Inhalation Anaesthetics may conversely diminish the uterotonic effect. Use is also contraindicated in patients with severe hepatic or renal impairment due to the impact of these conditions on the body’s ability to clear the medicine.

Dual-Component Agonism of Uterine Receptors

Syntometrine operates via a dual-component agonism, where oxytocin and ergometrine components activate target receptors on the uterine smooth muscle. The oxytocin component directly activates oxytocin receptors ( OTR), while ergometrine targets alpha-adrenergic and serotonergic receptors, influencing the overall contractile stimulus. This dual engagement promotes a sustained and tonic contraction profile, resulting in a rapid and prolonged contraction and retraction of the uterus. This mechanical effect leads to the compression and constriction of the uterine blood vessels within the placental bed.

Intracellular Calcium Cascade

Receptor binding triggers the phospholipase C ( PLC) pathway, leading to the generation of inositol triphosphate ( IP3) and the subsequent release of sequestered intracellular calcium (Ca^2+). This mechanism focuses on increasing Ca^2+ availability, which is the necessary molecular signal to drive actin-myosin cross-bridge cycling. The sustained high Ca^2+ levels underpin the resultant tonic uterine contraction and enduring muscle shortening.

Influencing Myometrial Tone and Frequency

The combined actions drive the muscle fibers into a state of tetanic contraction, characterized by increased basal tone (hypertonus) and frequency of contractions. This hypertonic activity creates a physical compressive force across the myometrium, assisting in the closure of vessels and maintaining uterine rigidity.

How Syntometrine Is Used

Syntometrine is a specialized, fixed-dose combination medication administered exclusively as a solution for injection in a supervised clinical setting, strictly following defined obstetrical protocols. Its use is defined by precise timing and administration constraints, reflecting its role as an acute intervention.

---

Administration Route and Dosing

The medication is administered via the intramuscular (IM) route as the standard procedure, or alternatively, via the intravenous (IV) route. The dosage is a single 1 mL ampoule, which delivers a fixed combination of 500 mu g Ergometrine maleate and 5 I.U. Oxytocin. Since this is an acute, procedural drug, there are no ongoing maintenance regimens or cyclical use patterns.

---

Procedural Timing and Constraints

Official instructions mandate that the single dose must be administered at a highly specific point during labor management: immediately following the delivery of the anterior shoulder or, at the latest, immediately after the birth of the baby. The medication must not be given prior to the delivery of the anterior shoulder or before the last child has been delivered in cases of multiple births.

If the IV route is chosen, the injection must be given slowly, typically over at least 60 seconds. In situations requiring subsequent control of postpartum hemorrhage, the total dose administered should generally not exceed 3 mL within a 24-hour period, and repeat injections require an interval of no less than two hours.

---

Population Considerations

The product is not indicated for use in children, and due to its acute usage context, official prescribing information does not define routine dose adjustments for older adults or for patients with renal or hepatic impairment.

Research Evidence: Overview of Studies for Syntometrine

This overview provides a factual summary of the research that has explored the combination medicine Syntometrine. It describes the structure of the evidence base, the types of studies that have been conducted, and what aspects of the medicine’s use remain uncertain, without making any claims of effectiveness or offering clinical advice.

---

Evidence for Use in Managing the Third Stage of Labor

The main clinical research for Syntometrine was studied for its role in the active management of the third stage of labor—the period immediately following childbirth. The research evaluated this medication in trials that monitored outcomes for excessive blood loss, known as postpartum hemorrhage (PPH).

The evidence base primarily relies on large, short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that combine data from numerous comparative studies. Researchers tracked metrics related to blood loss (e.g., incidence of Postpartum Hemorrhage (PPH) defined by blood loss 500 mL) and the requirement for additional uterotonic medication or procedures.

Some studies describe patterns where measurements of PPH incidence (500 mL) were examined in groups receiving the combination drug compared to groups receiving other specific agents. Research reports documented changes measured during the study period, describing that the combination was associated with a higher frequency of certain maternal adverse effects, such as nausea and vomiting, in the studied populations.

---

Understanding Study Comparisons and Measured Outcomes

The clinical trials for Syntometrine examined data in comparison to other standard treatments. Researchers examined different metrics tracked during the study period, including measuring the mean estimated blood loss (EBL). Findings describe group patterns, not personal outcomes, reflecting the specific conditions under which the studies were conducted.

The evidence contributes to understanding symptom patterns, but findings were mixed when researchers examined the specific outcome of severe PPH (blood loss 1000 mL). Data show patterns related to less clear differences between the combination drug and Oxytocin alone for this severe outcome.

---

Key Limitations and Remaining Research Uncertainty

One key limitation noted across the scientific literature is a trade-off between the measured outcomes related to blood loss and the frequency of certain maternal adverse effects that was associated with the combination drug.

Data for certain groups remain insufficient. There is an absence of data for use in elderly or pediatric populations in this context. Because trials were designed to assess immediate outcomes, long-term outcomes are not fully established in the existing clinical research.

Key Studies & References Oxytocin (Synthetic) and Ergometrine Maleate (Syntometrine®) Adult Medication Guideline (WNHS)

Common questions about Syntometrine (FAQ)

---

Q: Is Syntometrine an essential part of the labor process?

The World Health Organization (WHO) includes this combination medicine as one of the recommended uterotonics for the prevention of postpartum hemorrhage (PPH) during the third stage of labor. Its administration is defined as part of the Active Management of the Third Stage of Labor, which is a standard procedure used to manage the risk of excessive bleeding.

---

Q: How quickly does Syntometrine typically start working?

Official product information indicates that following an intramuscular injection, the drug's effect on the uterus typically begins quickly. The documented time for the start of the uterine response, or latent period, is about 2frac12 minutes.

---

Q: How long do the effects of Syntometrine last in the body?

The primary action of the medicine, which is to cause the uterus to contract, is described as prolonged. The uterotonic effect usually lasts for several hours. Regulatory documents specify that if a repeat injection is considered, it should be administered with an interval of not less than two hours between doses.

---

Q: Is Syntometrine used in all countries for preventing bleeding after delivery?

The fixed-dose combination of Oxytocin and Ergometrine is recognized internationally for its clinical importance. The World Health Organization (WHO) includes it on the Model List of Essential Medicines for use as a uterotonic agent to prevent bleeding after delivery.

---

Q: Is it normal to feel a cramping sensation after receiving Syntometrine?

Official product information reports that the medicine works by causing the uterus to contract strongly and rhythmically. As a result of this action, documented side effects include 'pain in the abdomen that is different from labour pains.'

---

Q: Why do some people receive a different medicine instead of Syntometrine?

Clinical guidelines recognize several uterotonic agents for preventing postpartum bleeding. The choice is based on established protocols and contraindications. For example, Syntometrine is contraindicated in certain severe hypertensive conditions, which may lead to the use of an alternative agent. Research reports also note that the combination drug has been associated with a higher frequency of certain documented adverse effects like nausea and vomiting.

---

Q: Do studies suggest Syntometrine is generally effective for its intended purpose?

Studies examining this medication focus on tracking metrics related to blood loss, such as the incidence of postpartum hemorrhage (PPH). The evidence indicates patterns where its use was associated with certain measured outcomes related to moderate PPH (defined as blood loss of 500 mL or more). Research reports sometimes note an associated higher rate of certain documented side effects in the populations studied.

---

Q: What happens to the drug in the body after its job is done?

The two active components of the medicine are processed and cleared by the body through different mechanisms. Official product information describes that the Oxytocin component is rapidly broken down and cleared by the liver and kidneys. The Ergometrine component, however, is mainly broken down (metabolized) in the liver before being eliminated from the body.

---

Q: Why is Syntometrine not given before the baby is delivered?

Regulatory documents explicitly state that this medicine must not be administered before the delivery of the anterior shoulder or before the last child in a multiple birth. This strict rule exists because the Ergometrine component is a very powerful uterotonic agent that stimulates strong uterine contractions. Giving it too early could interfere with the normal delivery process.

---

Q: Does Syntometrine carry a specific safety classification during its use in labor?

The drug is used specifically in the immediate period after delivery. However, official regulatory documents carry a general warning related to its classification as Reproductive Toxicity Category 1B. This general hazard statement indicates the compound 'May damage fertility or the unborn child,' but the drug is only approved for use after delivery.

How to Store and Dispose of Syntometrine

The storage of Syntometrine (Ergometrine maleate/Oxytocin Solution for Injection) is strictly controlled by regulatory labeling to maintain product stability and potency.

Storage Requirements

Condition	Requirement
Long-Term Temperature	Mandatory refrigeration: Store between 2 C and 8 C.
Protection	Protect from light; keep ampoules in the original outer carton.
Temporary Storage	May be stored up to 25 C for a maximum of two months, after which the product must be discarded.
Child Safety	Keep out of the sight and reach of children.

Disposal

Disposal of any unused or expired medicinal product must be carried out in accordance with local requirements.

The medicine must not be disposed of via wastewater or standard household waste; consult a pharmacist regarding proper disposal procedures.